Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]N. S. Bryan, K. Bian and F. Murad: Discovery of the nitric oxide signaling pathway and targets for drug development. Front Biosci (Landmark Ed), 14, 1-18 (2009)

  • [2]J. S. Beckman, T. W. Beckman, J. Chen, P. A. Marshall and B. A. Freeman: Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci U S A, 87(4), 1620-4 (1990)

  • [3]L. Castro and B. A. Freeman: Reactive oxygen species in human health and disease. Nutrition, 17(2), 161, 163-5 (2001)

  • [4]F. J. Schopfer, C. Cipollina and B. A. Freeman: Formation and signaling actions of electrophilic lipids. Chem Rev, 111(10), 5997-6021 (2011)

  • [5]M. Fazzari, N. Khoo, S. R. Woodcock, L. Li, B. A. Freeman and F. J. Schopfer: Generation and esterification of electrophilic fatty acid nitroalkenes in triacylglycerides. Free Radic Biol Med (2015)

  • [6]M. Delmastro-Greenwood, B. A. Freeman and S. G. Wendell: Redox-dependent anti-inflammatory signaling actions of unsaturated fatty acids. Annu Rev Physiol, 76, 79-105 (2014)

  • [7]M. P. Cole, T. K. Rudolph, N. K. Khoo, U. N. Motanya, F. Golin-Bisello, J. W. Wertz, F. J. Schopfer, V. Rudolph, S. R. Woodcock, S. Bolisetty, M. S. Ali, J. Zhang, Y. E. Chen, A. Agarwal, B. A. Freeman and P. M. Bauer: Nitro-fatty acid inhibition of neointima formation after endoluminal vessel injury. Circ Res, 105(10), 965-72 (2009)

  • [8]S. M. Nadtochiy, P. R. Baker, B. A. Freeman and P. S. Brookes: Mitochondrial nitroalkene formation and mild uncoupling in ischaemic preconditioning: implications for cardioprotection. Cardiovasc Res, 82(2), 333-40 (2009)

  • [9]J. Zhang, L. Villacorta, L. Chang, Z. Fan, M. Hamblin, T. Zhu, C. S. Chen, M. P. Cole, F. J. Schopfer, C. X. Deng, M. T. Garcia-Barrio, Y. H. Feng, B. A. Freeman and Y. E. Chen: Nitro-oleic acid inhibits angiotensin II-induced hypertension. Circ Res, 107(4), 540-8 (2010)

  • [10]T. K. Rudolph, V. Rudolph, M. M. Edreira, M. P. Cole, G. Bonacci, F. J. Schopfer, S. R. Woodcock, A. Franek, M. Pekarova, N. K. Khoo, A. H. Hasty, S. Baldus and B. A. Freeman: Nitro-fatty acids reduce atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol, 30(5), 938-45 (2010)

  • [11]P. R. Baker, F. J. Schopfer, V. B. O’Donnell and B. A. Freeman: Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids. Free Radic Biol Med, 46(8), 989-1003 (2009)

  • [12]V. Rudolph and B. A. Freeman: Cardiovascular consequences when nitric oxide and lipid signaling converge. Circ Res, 105(6), 511-22 (2009)

  • [13]I. Parastatidis, L. Thomson, D. M. Fries, R. E. Moore, J. Tohyama, X. Fu, S. L. Hazen, H. F. Heijnen, M. K. Dennehy, D. C. Liebler, D. J. Rader and H. Ischiropoulos: Increased protein nitration burden in the atherosclerotic lesions and plasma of apolipoprotein A-I deficient mice. Circ Res, 101(4), 368-76 (2007)

  • [14]M. H. Shishehbor, R. J. Aviles, M. L. Brennan, X. Fu, M. Goormastic, G. L. Pearce, N. Gokce, J. F. Keaney, Jr., M. S. Penn, D. L. Sprecher, J. A. Vita and S. L. Hazen: Association of nitrotyrosine levels with cardiovascular disease and modulation by statin therapy. JAMA, 289(13), 1675-80 (2003)

  • [15]N. K. Khoo and B. A. Freeman: Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment. Curr Opin Pharmacol, 10(2), 179-84 (2010)

  • [16]E. S. Lima, P. Di Mascio, H. Rubbo and D. S. Abdalla: Characterization of linoleic acid nitration in human blood plasma by mass spectrometry. Biochemistry, 41(34), 10717-22 (2002)

  • [17]D. G. Lim, S. Sweeney, A. Bloodsworth, C. R. White, P. H. Chumley, N. R. Krishna, F. Schopfer, V. B. O’Donnell, J. P. Eiserich and B. A. Freeman: Nitrolinoleate, a nitric oxide-derived mediator of cell function: synthesis, characterization, and vasomotor activity. Proc Natl Acad Sci U S A, 99(25), 15941-6 (2002)

  • [18]I. Milic, E. Griesser, V. Vemula, N. Ieda, H. Nakagawa, N. Miyata, J. M. Galano, C. Oger, T. Durand and M. Fedorova: Profiling and relative quantification of multiply nitrated and oxidized fatty acids. Anal Bioanal Chem, 407(19), 5587-602 (2015)

  • [19]G. Bonacci, P. R. Baker, S. R. Salvatore, D. Shores, N. K. Khoo, J. R. Koenitzer, D. A. Vitturi, S. R. Woodcock, F. Golin-Bisello, M. P. Cole, S. Watkins, C. St Croix, C. I. Batthyany, B. A. Freeman and F. J. Schopfer: Conjugated linoleic acid is a preferential substrate for fatty acid nitration. J Biol Chem, 287(53), 44071-82 (2012)

  • [20]S. R. Salvatore, D. A. Vitturi, P. R. Baker, G. Bonacci, J. R. Koenitzer, S. R. Woodcock, B. A. Freeman and F. J. Schopfer: Characterization and quantification of endogenous fatty acid nitroalkene metabolites in human urine. J Lipid Res, 54(7), 1998-2009 (2013)

  • [21]D. Tsikas, A. Zoerner, A. Mitschke, Y. Homsi, F. M. Gutzki and J. Jordan: Specific GC-MS/MS stable-isotope dilution methodology for free 9-and 10-nitro-oleic acid in human plasma challenges previous LC-MS/MS reports. J Chromatogr B Analyt Technol Biomed Life Sci, 877(26), 2895-908 (2009)

  • [22]V. Rudolph, T. K. Rudolph, F. J. Schopfer, G. Bonacci, S. R. Woodcock, M. P. Cole, P. R. Baker, R. Ramani and B. A. Freeman: Endogenous generation and protective effects of nitro-fatty acids in a murine model of focal cardiac ischaemia and reperfusion. Cardiovasc Res, 85(1), 155-66 (2010)

  • [23]D. A. Vitturi, L. Minarrieta, S. R. Salvatore, E. M. Postlethwait, M. Fazzari, G. Ferrer-Sueta, J. R. Lancaster, Jr., B. A. Freeman and F. J. Schopfer: Convergence of biological nitration and nitrosation via symmetrical nitrous anhydride. Nat Chem Biol, 11(7), 504-10 (2015)

  • [24]C. N. Serhan, G. Fredman, R. Yang, S. Karamnov, L. S. Belayev, N. G. Bazan, M. Zhu, J. W. Winkler and N. A. Petasis: Novel proresolving aspirin-triggered DHA pathway. Chem Biol, 18(8), 976-87 (2011)

  • [25]E. Weitzberg and J. O. Lundberg: Novel aspects of dietary nitrate and human health. Annu Rev Nutr, 33, 129-59 (2013)

  • [26]J. O. Lundberg, M. T. Gladwin, A. Ahluwalia, N. Benjamin, N. S. Bryan, A. Butler, P. Cabrales, A. Fago, M. Feelisch, P. C. Ford, B. A. Freeman, M. Frenneaux, J. Friedman, M. Kelm, C. G. Kevil, D. B. Kim-Shapiro, A. V. Kozlov, J. R. Lancaster, Jr., D. J. Lefer, K. McColl, K. McCurry, R. P. Patel, J. Petersson, T. Rassaf, V. P. Reutov, G. B. Richter-Addo, A. Schechter, S. Shiva, K. Tsuchiya, E. E. van Faassen, A. J. Webb, B. S. Zuckerbraun, J. L. Zweier and E. Weitzberg: Nitrate and nitrite in biology, nutrition and therapeutics. Nat Chem Biol, 5(12), 865-9 (2009)

  • [27]L. M. Baker, P. R. Baker, F. Golin-Bisello, F. J. Schopfer, M. Fink, S. R. Woodcock, B. P. Branchaud, R. Radi and B. A. Freeman: Nitro-fatty acid reaction with glutathione and cysteine. Kinetic analysis of thiol alkylation by a Michael addition reaction. J Biol Chem, 282(42), 31085-93 (2007)

  • [28]V. Rudolph, F. J. Schopfer, N. K. Khoo, T. K. Rudolph, M. P. Cole, S. R. Woodcock, G. Bonacci, A. L. Groeger, F. Golin-Bisello, C. S. Chen, P. R. Baker and B. A. Freeman: Nitro-fatty acid metabolome: saturation, desaturation, beta-oxidation, and protein adduction. J Biol Chem, 284(3), 1461-73 (2009)

  • [29]D. A. Vitturi, C. S. Chen, S. R. Woodcock, S. R. Salvatore, G. Bonacci, J. R. Koenitzer, N. A. Stewart, N. Wakabayashi, T. W. Kensler, B. A. Freeman and F. J. Schopfer: Modulation of Nitro-fatty Acid Signaling: prostaglandin reductase-1 is a nitroalkene reductase. J Biol Chem, 288(35), 25626-37 (2013)

  • [30]R. L. Alexander, D. J. Bates, M. W. Wright, S. B. King and C. S. Morrow: Modulation of nitrated lipid signaling by multidrug resistance protein 1 (MRP1): glutathione conjugation and MRP1-mediated efflux inhibit nitrolinoleic acid-induced, PPARgamma-dependent transcription activation. Biochemistry, 45(25), 7889-96 (2006)

  • [31]L. Villacorta, L. Chang, S. R. Salvatore, T. Ichikawa, J. Zhang, D. Petrovic-Djergovic, L. Jia, H. Carlsen, F. J. Schopfer, B. A. Freeman and Y. E. Chen: Electrophilic nitro-fatty acids inhibit vascular inflammation by disrupting LPS-dependent TLR4 signalling in lipid rafts. Cardiovasc Res, 98(1), 116-24 (2013)

  • [32]M. J. Gorczynski, J. Huang and S. B. King: Regio-and stereospecific syntheses and nitric oxide donor properties of (E)-9-and (E)-10-nitrooctadec-9-enoic acids. Org Lett, 8(11), 2305-8 (2006)

  • [33]M. J. Gorczynski, J. Huang, H. Lee and S. B. King: Evaluation of nitroalkenes as nitric oxide donors. Bioorg Med Chem Lett, 17(7), 2013-7 (2007)

  • [34]E. S. Lima, M. G. Bonini, O. Augusto, H. V. Barbeiro, H. P. Souza and D. S. Abdalla: Nitrated lipids decompose to nitric oxide and lipid radicals and cause vasorelaxation. Free Radic Biol Med, 39(4), 532-9 (2005)

  • [35]F. J. Schopfer, P. R. Baker, G. Giles, P. Chumley, C. Batthyany, J. Crawford, R. P. Patel, N. Hogg, B. P. Branchaud, J. R. Lancaster, Jr. and B. A. Freeman: Fatty acid transduction of nitric oxide signaling. Nitrolinoleic acid is a hydrophobically stabilized nitric oxide donor. J Biol Chem, 280(19), 19289-97 (2005)

  • [36]F. Blanco, A. M. Ferreira, G. V. Lopez, L. Bonilla, M. Gonzalez, H. Cerecetto, A. Trostchansky and H. Rubbo: 6-Methylnitroarachidonate: a novel esterified nitroalkene that potently inhibits platelet aggregation and exerts cGMP-mediated vascular relaxation. Free Radic Biol Med, 50(3), 411-8 (2011)

  • [37]A. N. Higdon, A. Landar, S. Barnes and V. M. Darley-Usmar: The electrophile responsive proteome: integrating proteomics and lipidomics with cellular function. Antioxid Redox Signal, 17(11), 1580-9 (2012)

  • [38]A. L. Levonen, B. G. Hill, E. Kansanen, J. Zhang and V. M. Darley-Usmar: Redox regulation of antioxidants, autophagy, and the response to stress: implications for electrophile therapeutics. Free Radic Biol Med, 71, 196-207 (2014)

  • [39]W. G. McMaster, A. Kirabo, M. S. Madhur and D. G. Harrison: Inflammation, immunity, and hypertensive end-organ damage. Circ Res, 116(6), 1022-33 (2015)

  • [40]F. J. Schopfer, Y. Lin, P. R. Baker, T. Cui, M. Garcia-Barrio, J. Zhang, K. Chen, Y. E. Chen and B. A. Freeman: Nitrolinoleic acid: an endogenous peroxisome proliferator-activated receptor gamma ligand. Proc Natl Acad Sci U S A, 102(7), 2340-5 (2005)

  • [41]Y. Li, J. Zhang, F. J. Schopfer, D. Martynowski, M. T. Garcia-Barrio, A. Kovach, K. Suino-Powell, P. R. Baker, B. A. Freeman, Y. E. Chen and H. E. Xu: Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol, 15(8), 865-7 (2008)

  • [42]T. Cui, F. J. Schopfer, J. Zhang, K. Chen, T. Ichikawa, P. R. Baker, C. Batthyany, B. K. Chacko, X. Feng, R. P. Patel, A. Agarwal, B. A. Freeman and Y. E. Chen: Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators. J Biol Chem, 281(47), 35686-98 (2006)

  • [43]L. Villacorta, J. Zhang, M. T. Garcia-Barrio, X. L. Chen, B. A. Freeman, Y. E. Chen and T. Cui: Nitro-linoleic acid inhibits vascular smooth muscle cell proliferation via the Keap1/Nrf2 signaling pathway. Am J Physiol Heart Circ Physiol, 293(1), H770-6 (2007)

  • [44]E. Kansanen, G. Bonacci, F. J. Schopfer, S. M. Kuosmanen, K. I. Tong, H. Leinonen, S. R. Woodcock, M. Yamamoto, C. Carlberg, S. Yla-Herttuala, B. A. Freeman and A. L. Levonen: Electrophilic nitro-fatty acids activate NRF2 by a KEAP1 cysteine 151-independent mechanism. J Biol Chem, 286(16), 14019-27 (2011)

  • [45]E. Kansanen, H. K. Jyrkkanen, O. L. Volger, H. Leinonen, A. M. Kivela, S. K. Hakkinen, S. R. Woodcock, F. J. Schopfer, A. J. Horrevoets, S. Yla-Herttuala, B. A. Freeman and A. L. Levonen: Nrf2-dependent and -independent responses to nitro-fatty acids in human endothelial cells: identification of heat shock response as the major pathway activated by nitro-oleic acid. J Biol Chem, 284(48), 33233-41 (2009)

  • [46]E. E. Kelley, C. I. Batthyany, N. J. Hundley, S. R. Woodcock, G. Bonacci, J. M. Del Rio, F. J. Schopfer, J. R. Lancaster, Jr., B. A. Freeman and M. M. Tarpey: Nitro-oleic acid, a novel and irreversible inhibitor of xanthine oxidoreductase. J Biol Chem, 283(52), 36176-84 (2008)

  • [47]S. M. Nadtochiy, Q. Zhu, W. Urciuoli, R. Rafikov, S. M. Black and P. S. Brookes: Nitroalkenes confer acute cardioprotection via adenine nucleotide translocase 1. J Biol Chem, 287(5), 3573-80 (2012)

  • [48]S. Guo, A. Olm-Shipman, A. Walters, W. R. Urciuoli, S. Devito, S. M. Nadtochiy, A. P. Wojtovich and P. S. Brookes: A cell-based phenotypic assay to identify cardioprotective agents. Circ Res, 110(7), 948-57 (2012)

  • [49]F. J. Schopfer, C. Batthyany, P. R. Baker, G. Bonacci, M. P. Cole, V. Rudolph, A. L. Groeger, T. K. Rudolph, S. Nadtochiy, P. S. Brookes and B. A. Freeman: Detection and quantification of protein adduction by electrophilic fatty acids: mitochondrial generation of fatty acid nitroalkene derivatives. Free Radic Biol Med, 46(9), 1250-9 (2009)

  • [50]G. Bonacci, F. J. Schopfer, C. I. Batthyany, T. K. Rudolph, V. Rudolph, N. K. Khoo, E. E. Kelley and B. A. Freeman: Electrophilic fatty acids regulate matrix metalloproteinase activity and expression. J Biol Chem, 286(18), 16074-81 (2011)

  • [51]J. Li, T. Ichikawa, L. Villacorta, J. S. Janicki, G. L. Brower, M. Yamamoto and T. Cui: Nrf2 protects against maladaptive cardiac responses to hemodynamic stress. Arterioscler Thromb Vasc Biol, 29(11), 1843-50 (2009)

  • [52]J. Krishnan, M. Suter, R. Windak, T. Krebs, A. Felley, C. Montessuit, M. Tokarska-Schlattner, E. Aasum, A. Bogdanova, E. Perriard, J. C. Perriard, T. Larsen, T. Pedrazzini and W. Krek: Activation of a HIF1alpha-PPARgamma axis underlies the integration of glycolytic and lipid anabolic pathways in pathologic cardiac hypertrophy. Cell Metab, 9(6), 512-24 (2009)

  • [53]K. M. Piell, N. Qipshidze Kelm, M. P. Caroway, M. Aman and M. P. Cole: Nitrite treatment rescues cardiac dysfunction in aged mice treated with conjugated linoleic acid. Free Radic Biol Med, 72, 66-75 (2014)

  • [54]N. Qipshidze-Kelm, K. M. Piell, J. C. Solinger and M. P. Cole: Co-treatment with conjugated linoleic acid and nitrite protects against myocardial infarction. Redox Biol, 2, 1-7 (2013)

  • [55]J. X. Wang, J. Q. Jiao, Q. Li, B. Long, K. Wang, J. P. Liu, Y. R. Li and P. F. Li: miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nat Med, 17(1), 71-8 (2011)

  • [56]S. M. Nadtochiy, J. Madukwe, F. Hagen and P. S. Brookes: Mitochondrially targeted nitro-linoleate: a new tool for the study of cardioprotection. Br J Pharmacol, 171(8), 2091-8 (2014)

  • [57]S. C. Kolwicz, Jr., S. Purohit and R. Tian: Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res, 113(5), 603-16 (2013)

  • [58]M. M. Wright, F. J. Schopfer, P. R. Baker, V. Vidyasagar, P. Powell, P. Chumley, K. E. Iles, B. A. Freeman and A. Agarwal: Fatty acid transduction of nitric oxide signaling: nitrolinoleic acid potently activates endothelial heme oxygenase 1 expression. Proc Natl Acad Sci U S A, 103(11), 4299-304 (2006)

  • [59]N. K. Khoo, V. Rudolph, M. P. Cole, F. Golin-Bisello, F. J. Schopfer, S. R. Woodcock, C. Batthyany and B. A. Freeman: Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids. Free Radic Biol Med, 48(2), 230-9 (2010)

  • [60]M. Rudnicki, L. A. Faine, N. Dehne, D. Namgaladze, S. Ferderbar, R. Weinlich, G. P. Amarante-Mendes, C. Y. Yan, J. E. Krieger, B. Brune and D. S. Abdalla: Hypoxia inducible factor-dependent regulation of angiogenesis by nitro-fatty acids. Arterioscler Thromb Vasc Biol, 31(6), 1360-7 (2011)

  • [61]A. L. Levonen, M. Inkala, T. Heikura, S. Jauhiainen, H. K. Jyrkkanen, E. Kansanen, K. Maatta, E. Romppanen, P. Turunen, J. Rutanen and S. Yla-Herttuala: Nrf2 gene transfer induces antioxidant enzymes and suppresses smooth muscle cell growth in vitro and reduces oxidative stress in rabbit aorta in vivo. Arterioscler Thromb Vasc Biol, 27(4), 741-7 (2007)

  • [62]P. Libby, I. Tabas, G. Fredman and E. A. Fisher: Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res, 114(12), 1867-79 (2014)

  • [63]T. Ichikawa, J. Zhang, K. Chen, Y. Liu, F. J. Schopfer, P. R. Baker, B. A. Freeman, Y. E. Chen and T. Cui: Nitroalkenes suppress lipopolysaccharide-induced signal transducer and activator of transcription signaling in macrophages: a critical role of mitogen-activated protein kinase phosphatase 1. Endocrinology, 149(8), 4086-94 (2008)

  • [64]M. Peled and E. A. Fisher: Dynamic Aspects of Macrophage polarization during atherosclerosis progression and regression. Front Immunol, 5, 579 (2014)

  • [65]M. A. Bouhlel, B. Derudas, E. Rigamonti, R. Dievart, J. Brozek, S. Haulon, C. Zawadzki, B. Jude, G. Torpier, N. Marx, B. Staels and G. Chinetti-Gbaguidi: PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab, 6(2), 137-43 (2007)

  • [66]J. I. Odegaard, R. R. Ricardo-Gonzalez, M. H. Goforth, C. R. Morel, V. Subramanian, L. Mukundan, A. Red Eagle, D. Vats, F. Brombacher, A. W. Ferrante and A. Chawla: Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature, 447(7148), 1116-20 (2007)

  • [67]J. S. Orr, M. J. Puglisi, K. L. Ellacott, C. N. Lumeng, D. H. Wasserman and A. H. Hasty: Toll-like receptor 4 deficiency promotes the alternative activation of adipose tissue macrophages. Diabetes, 61(11), 2718-27 (2012)

  • [68]A. Kadl, A. K. Meher, P. R. Sharma, M. Y. Lee, A. C. Doran, S. R. Johnstone, M. R. Elliott, F. Gruber, J. Han, W. Chen, T. Kensler, K. S. Ravichandran, B. E. Isakson, B. R. Wamhoff and N. Leitinger: Identification of a novel macrophage phenotype that develops in response to atherogenic phospholipids via Nrf2. Circ Res, 107(6), 737-46 (2010)

  • [69]A. K. Ruotsalainen, M. Inkala, M. E. Partanen, J. P. Lappalainen, E. Kansanen, P. I. Makinen, S. E. Heinonen, H. M. Laitinen, J. Heikkila, T. Vatanen, S. Horkko, M. Yamamoto, S. Yla-Herttuala, M. Jauhiainen and A. L. Levonen: The absence of macrophage Nrf2 promotes early atherogenesis. Cardiovasc Res, 98(1), 107-15 (2013)

  • [70]K. J. Moore, F. J. Sheedy and E. A. Fisher: Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol, 13(10), 709-21 (2013)

  • [71]B. Coles, A. Bloodsworth, S. R. Clark, M. J. Lewis, A. R. Cross, B. A. Freeman and V. B. O’Donnell: Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ Res, 91(5), 375-81 (2002)

  • [72]B. Coles, A. Bloodsworth, J. P. Eiserich, M. J. Coffey, R. M. McLoughlin, J. C. Giddings, M. J. Lewis, R. J. Haslam, B. A. Freeman and V. B. O’Donnell: Nitrolinoleate inhibits platelet activation by attenuating calcium mobilization and inducing phosphorylation of vasodilator-stimulated phosphoprotein through elevation of cAMP. J Biol Chem, 277(8), 5832-40 (2002)

  • [73]P. von Hundelshausen and M. M. Schmitt: Platelets and their chemokines in atherosclerosis-clinical applications. Front Physiol, 5, 294 (2014)

  • [74]A. Trostchansky, L. Bonilla, C. P. Thomas, V. B. O’Donnell, L. J. Marnett, R. Radi and H. Rubbo: Nitroarachidonic acid, a novel peroxidase inhibitor of prostaglandin endoperoxide H synthases 1 and 2. J Biol Chem, 286(15), 12891-900 (2011)

  • [75]R. L. Charles, O. Rudyk, O. Prysyazhna, A. Kamynina, J. Yang, C. Morisseau, B. D. Hammock, B. A. Freeman and P. Eaton: Protection from hypertension in mice by the Mediterranean diet is mediated by nitro fatty acid inhibition of soluble epoxide hydrolase. Proc Natl Acad Sci U S A, 111(22), 8167-72 (2014)

  • [76]C. Morisseau and B. D. Hammock: Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health. Annu Rev Pharmacol Toxicol, 53, 37-58 (2013)

  • [77]S. C. Palmer, D. Mavridis, E. Navarese, J. C. Craig, M. Tonelli, G. Salanti, N. Wiebe, M. Ruospo, D. C. Wheeler and G. F. Strippoli: Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet, 385(9982), 2047-56 (2015)

  • [78]Y. Liu, Z. Jia, S. Liu, M. Downton, G. Liu, Y. Du and T. Yang: Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. Am J Physiol Renal Physiol, 305(11), F1555-62 (2013)

  • [79]M. Rabinovitch, C. Guignabert, M. Humbert and M. R. Nicolls: Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension. Circ Res, 115(1), 165-75 (2014)

  • [80]K. Awwad, S. D. Steinbrink, T. Fromel, N. Lill, J. Isaak, A. K. Hafner, J. Roos, B. Hofmann, H. Heide, G. Geisslinger, D. Steinhilber, B. A. Freeman, T. J. Maier and I. Fleming: Electrophilic fatty acid species inhibit 5-lipoxygenase and attenuate sepsis-induced pulmonary inflammation. Antioxid Redox Signal, 20(17), 2667-80 (2014)

  • [81]A. T. Reddy, S. P. Lakshmi, S. Dornadula, S. Pinni, D. R. Rampa and R. C. Reddy: The nitrated fatty acid 10-nitro-oleate attenuates allergic airway disease. J Immunol, 191(5), 2053-63 (2013)

  • [82]A. Klinke, A. Moller, M. Pekarova, T. Ravekes, K. Friedrichs, M. Berlin, K. M. Scheu, L. Kubala, H. Kolarova, G. Ambrozova, R. T. Schermuly, S. R. Woodcock, B. A. Freeman, S. Rosenkranz, S. Baldus, V. Rudolph and T. K. Rudolph: Protective Effects of 10-nitro-oleic Acid in a Hypoxia-Induced Murine Model of Pulmonary Hypertension. Am J Respir Cell Mol Biol, 51(1), 155-62 (2014)

  • [83]T. P. Alastalo, M. Li, J. Perez Vde, D. Pham, H. Sawada, J. K. Wang, M. Koskenvuo, L. Wang, B. A. Freeman, H. Y. Chang and M. Rabinovitch: Disruption of PPARgamma/beta-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest, 121(9), 3735-46 (2011)

  • [84]D. M. Gopal, R. Santhanakrishnan, Y. C. Wang, N. Ayalon, C. Donohue, Y. Rahban, A. J. Perez, J. Downing, C. S. Liang, N. Gokce, W. S. Colucci and J. E. Ho: Impaired right ventricular hemodynamics indicate preclinical pulmonary hypertension in patients with metabolic syndrome. J Am Heart Assoc, 4(3), e001597 (2015)

  • [85]G. Hansmann, R. A. Wagner, S. Schellong, V. A. Perez, T. Urashima, L. Wang, A. Y. Sheikh, R. S. Suen, D. J. Stewart and M. Rabinovitch: Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation, 115(10), 1275-84 (2007)

  • [86]E. E. Kelley, J. Baust, G. Bonacci, F. Golin-Bisello, J. E. Devlin, C. M. St Croix, S. C. Watkins, S. Gor, N. Cantu-Medellin, E. R. Weidert, J. C. Frisbee, M. T. Gladwin, H. C. Champion, B. A. Freeman and N. K. Khoo: Fatty acid nitroalkenes ameliorate glucose intolerance and pulmonary hypertension in high-fat diet-induced obesity. Cardiovasc Res, 101(3), 352-63 (2014)

  • [87]A. T. Reddy, S. P. Lakshmi, Y. Zhang and R. C. Reddy: Nitrated fatty acids reverse pulmonary fibrosis by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages. FASEB J, 28(12), 5299-310 (2014)

  • [88]F. Husain-Syed, P. A. McCullough, H. W. Birk, M. Renker, A. Brocca, W. Seeger and C. Ronco: Cardio-Pulmonary-Renal Interactions: A Multidisciplinary Approach. J Am Coll Cardiol, 65(22), 2433-2448 (2015)

  • [89]M. C. Menon, P. Y. Chuang and J. C. He: Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease. Am J Physiol Renal Physiol, 305(11), F1542-3 (2013)

  • [90]H. Wang, Z. Jia, J. Sun, L. Xu, B. Zhao, K. Yu, M. Yang, T. Yang and R. Wang: Nitrooleic acid protects against cisplatin nephropathy: role of COX-2/mPGES-1/PGE2 cascade. Mediators Inflamm, 2015, 293474 (2015)

  • [91]H. Wang, H. Liu, Z. Jia, C. Olsen, S. Litwin, G. Guan and T. Yang: Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice. Am J Physiol Renal Physiol, 298(3), F754-62 (2010)

  • [92]H. Liu, Z. Jia, S. Soodvilai, G. Guan, M. H. Wang, Z. Dong, J. D. Symons and T. Yang: Nitro-oleic acid protects the mouse kidney from ischemia and reperfusion injury. Am J Physiol Renal Physiol, 295(4), F942-9 (2008)

  • [93]L. Villacorta, F. J. Schopfer, J. Zhang, B. A. Freeman and Y. E. Chen: PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond), 116(3), 205-18 (2009)

  • [94]P. R. Baker, Y. Lin, F. J. Schopfer, S. R. Woodcock, A. L. Groeger, C. Batthyany, S. Sweeney, M. H. Long, K. E. Iles, L. M. Baker, B. P. Branchaud, Y. E. Chen and B. A. Freeman: Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem, 280(51), 42464-75 (2005)

  • [95]F. J. Schopfer, M. P. Cole, A. L. Groeger, C. S. Chen, N. K. Khoo, S. R. Woodcock, F. Golin-Bisello, U. N. Motanya, Y. Li, J. Zhang, M. T. Garcia-Barrio, T. K. Rudolph, V. Rudolph, G. Bonacci, P. R. Baker, H. E. Xu, C. I. Batthyany, Y. E. Chen, T. M. Hallis and B. A. Freeman: Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions. J Biol Chem, 285(16), 12321-33 (2010)

  • [96]A. M. Ferreira, M. I. Ferrari, A. Trostchansky, C. Batthyany, J. M. Souza, M. N. Alvarez, G. V. Lopez, P. R. Baker, F. J. Schopfer, V. O’Donnell, B. A. Freeman and H. Rubbo: Macrophage activation induces formation of the anti-inflammatory lipid cholesteryl-nitrolinoleate. Biochem J, 417(1), 223-34 (2009)

  • [97]E. S. Lima, P. Di Mascio and D. S. Abdalla: Cholesteryl nitrolinoleate, a nitrated lipid present in human blood plasma and lipoproteins. J Lipid Res, 44(9), 1660-6 (2003)

  • [98]H. Wang, H. Liu, Z. Jia, G. Guan and T. Yang: Effects of Endogenous PPAR Agonist Nitro-oleic acid on metabolic syndrome in obese Zucker rats. PPAR Res, 2010, 601562 (2010)

  • [99]H. Wang, J. Sun, Z. Jia, T. Yang, L. Xu, B. Zhao, K. Yu and R. Wang: Nitrooleic acid attenuates lipid metabolic disorders and liver steatosis in DOCA-salt hypertensive mice. PPAR Res, 2015, 480348 (2015)

  • [100]G. Wang, Y. Ji, Z. Li, X. Han, N. Guo, Q. Song, L. Quan, T. Wang, W. Han, D. Pang, H. Ouyang and X. Tang: Nitro-oleic acid downregulates lipoprotein-associated phospholipase A2 expression via the p42/p44 MAPK and NFkappaB pathways. Sci Rep, 4, 4905 (2014)

  • [101]S. Borniquel, E. A. Jansson, M. P. Cole, B. A. Freeman and J. O. Lundberg: Nitrated oleic acid up-regulates PPARgamma and attenuates experimental inflammatory bowel disease. Free Radic Biol Med, 48(4), 499-505 (2010)

  • [102]S. P. Lakshmi, A. T. Reddy, Y. Zhang, F. C. Sciurba, R. K. Mallampalli, S. R. Duncan and R. C. Reddy: Down-regulated peroxisome proliferator-activated receptor gamma (PPARgamma) in lung epithelial cells promotes a PPARgamma agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD). J Biol Chem, 289(10), 6383-93 (2014)

  • [103]D. E. Artim, F. Bazely, S. L. Daugherty, A. Sculptoreanu, K. B. Koronowski, F. J. Schopfer, S. R. Woodcock, B. A. Freeman and W. C. de Groat: Nitro-oleic acid targets transient receptor potential (TRP) channels in capsaicin sensitive afferent nerves of rat urinary bladder. Exp Neurol, 232(1), 90-9 (2011)

  • [104]A. Sculptoreanu, F. A. Kullmann, D. E. Artim, F. A. Bazley, F. Schopfer, S. Woodcock, B. A. Freeman and W. C. de Groat: Nitro-oleic acid inhibits firing and activates TRPV1-and TRPA1-mediated inward currents in dorsal root ganglion neurons from adult male rats. J Pharmacol Exp Ther, 333(3), 883-95 (2010)

  • [105]X. Zhang, J. M. Beckel, S. L. Daugherty, T. Wang, S. R. Woodcock, B. A. Freeman and W. C. de Groat: Activation of TRPC channels contributes to OA-NO2-induced responses in guinea-pig dorsal root ganglion neurons. J Physiol, 592(Pt 19), 4297-312 (2014)

  • [106]G. S. Harmon, M. T. Lam and C. K. Glass: PPARs and lipid ligands in inflammation and metabolism. Chem Rev, 111(10), 6321-40 (2011)

  • [107]R. L. Proia and T. Hla: Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J Clin Invest, 125(4), 1379-87 (2015)

  • [108]M. Spite and C. N. Serhan: Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res, 107(10), 1170-84 (2010)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jan 2016Review

Nitro-fatty acids in cardiovascular regulation and diseases: characteristics and molecular mechanisms

Luis Villacorta 1,*, Zhen Gao 1, Francisco J. Schopfer 2, Bruce A. Freeman 2, Y. Eugene Chen 1
Affiliations
Article Info

1 Cardiovascular Center, Department of Internal Medicine, University of Michigan, North Campus Research Complex 26, 2800 Plymouth Road, Ann Arbor, MI 48109, USA

2 Department of Pharmacology and Chemical Biology, University of Pittsburgh, E1343 Thomas E. Starzl Biomedical Science Tower, 200 Lothrop Street, Pittsburgh, PA 15213, USA

Abstract

Electrophilic nitro-fatty acids (NO2-FAs) are endogenously formed by redox reactions of nitric oxide (•NO)-and nitrite (•NO2)-derived nitrogen dioxide with unsaturated fatty acids. Nitration preferentially occurs on polyunsaturated fatty acids with conjugated dienes under physiological or pathophysiological conditions such as during digestion, metabolism and as adaptive inflammatory processes. Nitro-fatty acids are present in free and esterified forms achieving broad biodistribution in humans and experimental models. Structural, functional and biological characterization of NO2-FAs has revealed clinically relevant protection from inflammatory injury in a number of cardiovascular, renal and metabolic experimental models. NO2-FAs are engaged in posttranslational modifications (PTMs) of a selective redox sensitive pool of proteins and regulate key adaptive signaling pathways involved in cellular homeostasis and inflammatory response. Here, we review and update the biosynthesis, metabolism and signaling actions of NO2-FAs, highlighting their diverse protective roles relevant to the cardiovascular system.

Keywords

  • Nitro-fatty acids
  • Cardiovascular Diseases
  • Nitrite
  • Nitrate
  • Therapeutics
  • Inflammation
  • Metabolism
  • Review

References